Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 9/20 | 0.85 |
| ▸ | DRD2 | P14416 | 9/20 | 0.85 |
| ▸ | HRH1 | P35367 | 9/20 | 0.85 |
| ▸ | HTR1A | P08908 | 8/20 | 0.85 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.85 |
| ▸ | ADRA1A | P35348 | 8/20 | 0.85 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.85 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.85 |
| ▸ | ADRA2A | P08913 | 7/20 | 0.85 |
| ▸ | ADRA2B | P18089 | 7/20 | 0.85 |
| ▸ | ADRA2C | P18825 | 7/20 | 0.85 |
| ▸ | HTR2A | P28223 | 7/20 | 0.85 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.85 |
| ▸ | DRD1 | P21728 | 6/20 | 0.85 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.85 |
| ▸ | HTR2C | P28335 | 6/20 | 0.85 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.85 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.85 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.85 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thioproperazine SCHEMBL29372322 | 0.92 | DRD3 (1.00) | DRD3DRD2HRH1HTR1ASLC6A2 | |
| Thioproperazine SCHEMBL29394708 | 0.92 | DRD3 (1.00) | DRD3DRD2HRH1HTR1ASLC6A2 | |
| Thioproperazine SCHEMBL49902 | 0.92 | DRD3 (1.00) | DRD3DRD2HRH1HTR1ASLC6A2 | |
| Thioproperazine SCHEMBL28086631 | 0.91 | DRD3 (0.79) | DRD3DRD2HRH1HTR1ASLC6A2 | |
| Thioproperazine SCHEMBL3027811 | 0.90 | CYP3A4 (1.00) | DRD3DRD2HRH1HTR1ASLC6A2 | |
| Thioproperazine SCHEMBL2386850 | 0.90 | CYP3A4 (1.00) | DRD3DRD2HRH1HTR1ASLC6A2 | |
| Thioproperazine SCHEMBL29888916 | 0.90 | CYP3A4 (1.00) | DRD3DRD2HRH1HTR1ASLC6A2 | |
| SCHEMBL10136896 | 0.90 | DRD2 (0.85) | DRD3DRD2HRH1HTR1ASLC6A2 | |
| SCHEMBL10136838 | 0.90 | DRD3 (0.85) | DRD3DRD2HRH1HTR1ASLC6A2 | |
| SCHEMBL10136877 | 0.90 | DRD3 (0.85) | DRD3DRD2HRH1HTR1ASLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND | 2013-10-31 | — | — | US | disclosed |
| US-8475804-B2 | Compositions and methods for treatment of filovirus-mediated diseases | U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND (US) | 2013-07-02 | — | — | US | disclosed |
| US-8475804-B2 | Compositions and methods for treatment of filovirus-mediated diseases | U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND (US) | 2013-07-02 | — | — | US | disclosed |
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | ZALICUS INC. | 2011-02-03 | — | — | US | disclosed |
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | ZALICUS INC. | 2011-02-03 | — | — | US | disclosed |
| US-20070299043-A1 | Anti-scarring drug combinations and use thereof | HUNTER WILLIAM L | 2007-12-27 | — | — | US | disclosed |
| US-20070299043-A1 | Anti-scarring drug combinations and use thereof | HUNTER WILLIAM L | 2007-12-27 | — | — | US | disclosed |
| US-20070208134-A1 | Anti-scarring drug combinations and use thereof | HUNTER WILLIAM L | 2007-09-06 | — | — | US | disclosed |
| US-20070208134-A1 | Anti-scarring drug combinations and use thereof | HUNTER WILLIAM L | 2007-09-06 | — | — | US | disclosed |
| US-20070196421-A1 | Soft tissue implants and drug combination compositions, and use thereof | ANGIOTECH INTERNATIONAL AG (CH) | 2007-08-23 | — | — | US | disclosed |
| US-20070196421-A1 | Soft tissue implants and drug combination compositions, and use thereof | ANGIOTECH INTERNATIONAL AG (CH) | 2007-08-23 | — | — | US | disclosed |
| US-20070198063-A1 | Electrical devices and anti-scarring drug combinations | HUNTER WILLIAM L | 2007-08-23 | — | — | US | disclosed |
| US-20070198063-A1 | Electrical devices and anti-scarring drug combinations | HUNTER WILLIAM L | 2007-08-23 | — | — | US | disclosed |
| US-20070197957-A1 | Implantable sensors, implantable pumps and anti-scarring drug combinations | HUNTER WILLIAM L | 2007-08-23 | — | — | US | disclosed |
| US-20070197957-A1 | Implantable sensors, implantable pumps and anti-scarring drug combinations | HUNTER WILLIAM L | 2007-08-23 | — | — | US | disclosed |
| WO-2007041584-A2 | IMPLANTABLE SENSORS, IMPLANTABLE PUMPS, AND ANTI-SCARRING DRUG COMBINATIONS | COMBINATORX, INCORPORATED (US) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007041593-A2 | ANTI-SCARRING DRUG COMBINATIONS AND USE THEREOF | COMBINATORX, INCORPORATED (US) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007041463-A2 | ELECTRICAL DEVICES AND ANTI-SCARRING DRUG COMBINATIONS | COMBINATORX, INCORPORATED (US) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | DRD3 4854/4885DRD2 4871/4885HRH1 2998/4885 |
| US-20070208134-A1 | Anti-scarring drug combinations and use thereof | MMP1, COL2A1, COL1A1 | DRD3 3148/4885DRD2 3169/4885HRH1 2332/4885 |
| US-20070196421-A1 | Soft tissue implants and drug combination compositions, and use thereof | COL2A1, MMP1, FN1 | DRD3 4038/4885DRD2 3577/4885HRH1 2342/4885 |
| US-20070299043-A1 | Anti-scarring drug combinations and use thereof | MMP1, COL2A1, COL1A1 | DRD3 3148/4885DRD2 3169/4885HRH1 2332/4885 |
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | DRD3 4854/4885DRD2 4871/4885HRH1 2998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.